Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

"Oncolytic virus therapy" uses human viruses to fight cancer. Glioblastoma is a type of brain cancer that has recently been quite visible in the media after Sen. John McCain was treated for it.

Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028" report has been added to ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Cancer Therapy Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering. The oncolytic virus cancer ...

The company’s market cap currently stands at $84.5m. Oncolytic virus therapies have struggled to find a sure footing in the cancer immunotherapy landscape, which is dominated by checkpoint ...

In a study published Nov. 10 in Nature, the researchers described how they packed two different therapies into a single oncolytic virus—a virus that is used to destroy cancer cells—to hit GBM ...

Image credit: Amornrat Phuchom/Getty Images. Researchers investigated a novel combination treatment involving an oncolytic virus and immunotherapy for recurrent glioblastoma. The treatment increas ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Replimune’s lead program, an oncolytic virus, has fallen short in a study hoped to give patients one. The company is still pressing forward with its engineered virus in other types of skin ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.